Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CryoLife, a biomaterials, medical device and tissue processing company, has begun distribution in France, through Laboratoire Gamida, of Hemostase MPH for use in general, cardiac and vascular surgery.
Subscribe to our email newsletter
CryoLife began distributing Hemostase MPH in the US, the UK and Germany in the second quarter of 2008. Distribution in other markets outside the US is planned for later in 2008 and in 2009.
According to the company, Hemostase MPH, unlike many hemostatic agents, does not require additional operating room preparation or special storage conditions. In addition, preclinical evaluations have shown that Hemostase MPH does not promote infection and absorbs within 24-48 hours of application at the wound site, compared to other surgical hemostats which can take three to eight weeks or more to fully break down, said the company.
Hemostase MPH is developed using Microporous Polysaccharide Hemospheres (MPH) technology, which yields a plant-based powder engineered to rapidly dehydrate blood, enhancing clotting on contact. When used as directed, this hemostatic or antibleeding agent facilitates the formation of a resilient, natural clot within just a few minutes, the company said.
Steven Anderson, president and CEO of CryoLife, said: “As a complement to CryoLife’s BioGlue product line, Hemostase MPH gives surgeons the ability to quickly control active surgical bleeding, and we are pleased to begin offering this product in France.”